NBP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
NovaBridge Biosciences (NBP) is not a strong buy at the moment for a long-term beginner investor. While the stock has a positive analyst rating and potential upside in the long term, the lack of significant trading trends, weak financial performance, and absence of strong proprietary trading signals suggest holding off for now.
The MACD is positive but contracting, RSI is neutral at 36.961, and moving averages are converging, indicating no clear trend. The stock is trading near its pivot point of 2.555, with resistance at 2.727 and support at 2.383.
Analyst rating from H.C. Wainwright with a Buy recommendation and an increased price target of $9, citing the potential of givastomig as a best-in-class bispecific antibody.
No recent news or significant trading trends from hedge funds or insiders. Financial performance remains weak with negative net income and EPS, despite YoY improvements. Stock trend analysis suggests a short-term downside probability (-3.47% next day, -3.25% next week).
In Q4 2025, the company reported no revenue growth (0% YoY), a net income of -30.79M (up 239.74% YoY), and an EPS of -0.12 (up 140% YoY). Gross margin remained at 0%.
H.C. Wainwright resumed coverage with a Buy rating and raised the price target to $9 from $7, citing potential long-term growth driven by givastomig.
